Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Queensland Health
Argus Health
US Army
Accenture
Daiichi Sankyo
Baxter
Chubb
QuintilesIMS

Generated: April 19, 2018

DrugPatentWatch Database Preview

Sevelamer hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for sevelamer hydrochloride and what is the scope of sevelamer hydrochloride patent protection?

Sevelamer hydrochloride
is the generic ingredient in one branded drug marketed by Genzyme and is included in two NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sevelamer hydrochloride has forty-one patent family members in thirty-one countries.

There are thirty-two drug master file entries for sevelamer hydrochloride. Six suppliers are listed for this compound.
Summary for sevelamer hydrochloride
Pharmacology for sevelamer hydrochloride
Synonyms for sevelamer hydrochloride
(C3H7N)m.(C3H5ClO)n.(HCl)x
152751-57-0
182683-00-7
198343-01-0
2-(chloromethyl)oxirane; prop-2-en-1-amine; hydrochloride
2-Propen-1-amine polymer with (chloromethyl)oxirane hydrochloride
2-Propen-1-amine, hydrochloride, polymer with (chloromethyl)oxirane
2-propen-1-amine,hydrochloride,polymer with (chloromethyl)oxirane
AB01568265_01
AC-2089
AC1L4LHX
AC1Q3UBQ
AKOS025149504
Allylamine hydrochloride - epichlorhydrin copolymer
AN-14277
BC226808
CHEBI:32127
CTK4E2490
D01983
D03MZQ
FT-0653684
GLS2PGI8QG
GT 16-026A
HS-0082
KHNXRSIBRKBJDI-UHFFFAOYSA-N
LS-181811
MolPort-005-943-544
MolPort-039-138-690
Oxirane, (chloromethyl)-, polymer with 2-propen-1-amine hydrochloride
PB 94
Phosblock
prop-2-en-1-amine- 2-(chloromethyl)oxirane hydrochloride(1:1:1)
RenaGel
Renastat
Renestat
s4129
Sevelamer HCl
Sevelamer hydrochloride (JAN/USAN)
Sevelamer hydrochloride [USAN]
SEVELAMERHCL
UNII-GLS2PGI8QG

US Patents and Regulatory Information for sevelamer hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENAGEL sevelamer hydrochloride TABLET;ORAL 021179-001 Jul 12, 2000 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Genzyme RENAGEL sevelamer hydrochloride TABLET;ORAL 021179-002 Jul 12, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for sevelamer hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENAGEL sevelamer hydrochloride TABLET;ORAL 021179-001 Jul 12, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENAGEL sevelamer hydrochloride TABLET;ORAL 021179-001 Jul 12, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme RENAGEL sevelamer hydrochloride CAPSULE;ORAL 020926-001 Oct 30, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for sevelamer hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,187,631 Direct compression polymer tablet core ➤ Try a Free Trial
9,579,343 Direct compression polymer tablet core ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for sevelamer hydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0716606/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
C0011 France ➤ Try a Free Trial PRODUCT NAME: SEVELAMER; REGISTRATION NO/DATE: EU/1/99/123/001 20000128
/2009 Austria ➤ Try a Free Trial PRODUCT NAME: SEVELAMERCARBONAT; REGISTRATION NO/DATE: EU/1/09/521/001- EU/1/09/521/007 20090610
00428 Netherlands ➤ Try a Free Trial PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Cerilliant
Federal Trade Commission
Express Scripts
Farmers Insurance
Colorcon
Moodys
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.